It seems that the inhibition of the PI3K pathway may overcome this resistance, so it seems that the kind of mutation and subtype are important to predict clinical outcomes on BC [43,45], making these mutations useful for identifying more aggressive breast cancer tumors and predicting the response to PI3K pathway inhibitors [11]. Here, PIK3CA is linked to breast cancer.